A carregar...
Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
Background: We conducted a phase II study by combining FOLFOX4 plus bevacizumab (BV) with erlotinib (ER) as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC). Methods: Patients were divided into two groups in randomized double-blind manner. One group was given FOLFOX4 pl...
Na minha lista:
| Publicado no: | Am J Cancer Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
e-Century Publishing Corporation
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5622230/ https://ncbi.nlm.nih.gov/pubmed/28979818 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|